|
|
|
| Clinical effect of Nimotuzumab combined with Cisplatin concurrent che-moradiotherapy in the treatment of advanced nasopharyngeal carcinoma |
| CHEN Yangjing QUAN Fang WANG Lingu LI Honghui |
| Department of Otolaryngology Head and Neck Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Shaanxi Province, Xi'an 710061, China |
|
|
|
|
Abstract [Abstract] Objective To evaluate the clinical effect of Nimotuzumab combined with Cisplatin concurrent chemoradiotherapy in the treatment of advanced nasopharyngeal carcinoma. Methods According to different treating methods, 66 cases of patients with advanced nasopharyngeal carcinoma treated in the First Affiliated Hospital of Xi'an Jiaotong University from January 2011 to January 2013 were assigned into two groups. 33 cases in the control group received Cisplatin concurrent chemoradiotherapy treatment, while 33 cases in the observation group received Nimotuzumab combined with Cisplatin concurrent chemoradiotherapy. The efficacy of the two groups was compared. Results The total effective rate of observation group and control group was 84.85%, 60.61% respectively, the difference was highly statistically significant (P ＜ 0.01). The incidence of adverse reactions such as red blood cells decrease, thrombocytopenia, neutropenia, myelosuppression, skin reactions, radiation-induced oral mucositis, gastrointestinal reactions, electrocardiogram abnormalities, fever and others in the observation group was all significantly lower than those of control group, the differences were statistically significant (P ＜ 0.05 or P ＜ 0.01). The progression-free survival (PFS) of observation group was (6.4±0.4) months, and the median survival time (MST) was (14.6±1.8) months. For control group, the PFS was (4.2±0.6) months, and the MST was (11.1±1.5) months. The PFS and MST of observation group was obviously longer than those of control group (P ＜ 0.01). Conclusion Nimotuzumab combined with Cisplatin concurrent chemoradiotherapy in the treatment of advanced nasopharyngeal carcinoma can improve clinical effects significantly, with few side effects and high safety, which is worthy of clinical application.
|
|
|
|
|
|
[参考文献]
[1] 王亚利，马秀龙，任宏涛，等.DNA损伤修复基因与人鼻咽癌细胞辐射耐受CNE-2R细胞的相关性研究[J].西安交通大学学报：医学版，2015，36（2）：174-179.
[2] 丘文泽，黄培钰，施君理，等.调强放疗结合诱导化疗或同期加辅助化疗治疗局部晚期鼻咽癌的疗效比较[J].中国肿瘤临床，2015，42（4）：231-235.
[3] 陈建军，刘世喜，李启军，等.塞来昔布与顺铂联合应用抑制顺铂耐药性鼻咽癌细胞的生长并诱导其凋亡[J].细胞与分子免疫学杂志，2015，31（2）：203-206，211.
[4] 卢志文，黄树明，卢光，等.诱导化疗联合放疗治疗中晚期鼻咽癌42例的疗效[J].广东医学，2013，34（6）：917-919.
[5] 杨群英，沈冬，赛克，等.尼妥珠单抗联合化疗治疗恶性胶质瘤[J].中华肿瘤杂志，2011，33（3）：232-235.
[6] Tong HX，Huang H. Clinical observation of synchronou-schemotherapy and radiotherapy for nasopharyngeal carcinoma [J]. J Mod Oncol，2012，20（11）：2265-2267.
[7] 张天，孙权权，陈嘉荣，等.MicroRNA-451通过靶向RAB14抑制鼻咽癌细胞的生长、侵袭和迁移能力[J].实用医学杂志，2015，31（3）：355-360.
[8] 范育伟，齐立伟，李佳，等.多西他赛联合奈达铂同步调强适形放疗治疗局部晚期鼻咽癌的临床研究[J].中国肿瘤临床，2014，41（17）：1115-1119.
[9] 陈玉桂，汤日杰.直观弥散加权成像在鼻咽癌MR快速诊断中提高时间效能的价值[J].广东医学，2014，35（13）：2033-2036.
[10] 陈亚琼，周建荣，杨靖.鼻咽癌患者同步放化疗期间的症状群及影响因素研究[J].重庆医科大学学报，2014， 39（12）：1830-1834.
[11] 廖奎，陈华，万梁廷，等.国产图像引导放射治疗系统XGS在鼻咽癌调强放射治疗中的临床应用[J].重庆医学，2014，43（35）：4771-4773.
[12] 陈淑萍，周红桃，蔡俊宏，等.联合基因Survivin、CDK1的shRNAs靶向干扰对鼻咽癌CNE-2细胞增殖的影响[J].基因组学与应用生物学，2014，33（2）：239-247.
[13] 曹卡加，张爱兰，马文娟，等.奈达铂或顺铂联合5-氟尿嘧啶治疗鼻咽癌的随机对照研究[J].中华肿瘤杂志，2011，33（1）：50-52.
[14] 陈瑜，李娇阳，李茂玉，等.不同转移潜能鼻咽癌细胞株的差异膜蛋白质组研究[J].国际病理科学与临床杂志，2012，32（6）：479-487.
[15] 胡波，张新玲，周文营，等.EB病毒gp125蛋白的酵母表达及在鼻咽癌检测中的应用[J].中山大学学报：医学科学版，2014，35（5）：780-785.
[16] 刘艳，曾今诚，梁小泉，等.白细胞介素-35在鼻咽癌患者组织和外周血中的表达及意义[J].广东医学，2014， 35（22）：3533-3535.
[17] 刘丽娜.尼妥珠单抗与吉西他滨联合顺铂化疗方案在晚期胰腺癌治疗中的临床应用价值分析[J].中国现代药物应用，2015，9（7）：127-129.
[18] 卢奕宇，曹洋，杨文，等.芬太尼透皮贴剂联合尼美舒利治疗鼻咽癌放化疗中口腔黏膜损伤疼痛的临床疗效分析[J].肿瘤药学，2012，2（2）：116-119.
[19] 何苗，付岚，陈旭霞，等.巨和粒雾化吸入治疗鼻咽癌放射性口腔炎的疗效观察[J].成都医学院学报，2014，9（4）：431-433.
[20] 方盛华，陈艳贞，王碧荣，等.鼻咽癌骨转移患者的生存危险分层分析研究[J].现代医院，2015，15（3）：29-32.
[21] 张海荣，吴加满，赵余祥，等.鼻咽癌的CT表现及其与颈淋巴结转移的相关性分析[J].中国医药导报，2014， 11（16）：94-96，100.
[22] 杨宁，朱乐攀，谭潭，等.生存素下调多药耐药蛋白增强人鼻咽癌细胞株对紫杉醇敏感性的研究[J].中国医药导报，2014，11（8）：9-13，18.
[23] Sundvall M，Karrila A，Nordberg J，et al. EGFR targetingdrugs in the treatment of head and neck squamous cell carcinoma [J]. Expert Opin Emerg Drugs，2010，15（2）：185-201.
[24] Choi HJ，Sohn JH，Lee CG，et al. A phase Ⅰstudy of nimotuzumabin combination with radiotherapy in stagesⅡB-Ⅳ non-small cell lung cancer unsuitable for radical therapy：Koreanresults [J]. Lung Cancer，2011，71（1）：55-59. |
|
|
|
